fozivudine tidoxil

Fozivudine tidoxil is an investigational small molecule drug developed as a thioether lipid conjugate of zidovudine (AZT), designed to treat HIV infection. It acts as a nucleoside reverse transcriptase inhibitor (NRTI). After oral administration, it is cleaved intracellularly into a lipid moiety and zidovudine-monophosphate, which is then phosphorylated to the active metabolite, zidovudine-triphosphate. This design aims to increase intracellular concentrations of the active drug in mononuclear cells while reducing hematologic toxicity by limiting activation in red blood and stem cells. Fozivudine tidoxil has demonstrated anti-HIV activity in vitro and has undergone Phase II clinical trials for HIV infections[1][2][3][5][6][8].

Other names

fozivudine tidoxilfozivudinefoxivudine tidoxil